NURIX THERAPEUTICS, INC. Interest and Other Income
NURIX THERAPEUTICS, INC. (NRIX) reported Interest and Other Income of $4.40 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. interest and other income for the quarter ending 2026-05-31 was $4.40M, a 21.72% decline year-over-year.
- NURIX THERAPEUTICS, INC. interest and other income for the quarter ending 2026-02-28 was $5.32M, a 18.30% decline year-over-year.
- NURIX THERAPEUTICS, INC. interest and other income for the quarter ending 2025-11-30 was $4.87M, a 20.31% decline year-over-year.
- NURIX THERAPEUTICS, INC. interest and other income for the quarter ending 2025-08-31 was $4.96M, a 13.47% decline year-over-year.
- NURIX THERAPEUTICS, INC. interest and other income for fiscal 2025 was $21.97M, a 11.36% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. interest and other income for fiscal 2024 was $19.73M, a 77.49% increase from fiscal 2023.
- NURIX THERAPEUTICS, INC. interest and other income for fiscal 2023 was $11.12M, a 216.94% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. interest and other income for fiscal 2022 was $3.51M, a 326.12% increase from fiscal 2021.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-05-31 | $4.40M 10-Q · filed 2026-07-09 | $9.72M 10-Q · filed 2026-07-09 | $14.59M derived: sum of 3 quarters · filed 2026-07-09 | $19.56M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $5.32M 10-Q · filed 2026-04-08 | $10.20M derived: sum of 2 quarters · filed 2026-04-08 | $15.16M derived: sum of 3 quarters · filed 2026-04-08 | $20.78M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $9.84M derived: sum of 2 quarters · filed 2026-01-28 | $15.46M derived: sum of 3 quarters · filed 2026-07-09 | $21.97M 10-K · filed 2026-01-28 |
| 2025-08-31 | $4.96M 10-Q · filed 2025-10-09 | $10.58M derived: sum of 2 quarters · filed 2026-07-09 | $17.09M 10-Q · filed 2025-10-09 | $23.21M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $5.62M 10-Q · filed 2026-07-09 | $12.13M 10-Q · filed 2026-07-09 | $18.25M derived: sum of 3 quarters · filed 2026-07-09 | $23.98M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $6.51M 10-Q · filed 2026-04-08 | $12.63M derived: sum of 2 quarters · filed 2026-04-08 | $18.37M derived: sum of 3 quarters · filed 2026-04-08 | $22.45M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $11.85M derived: sum of 2 quarters · filed 2026-01-28 | $15.94M derived: sum of 3 quarters · filed 2026-01-28 | $19.73M 10-K · filed 2026-01-28 |
| 2024-08-31 | $5.74M 10-Q · filed 2025-10-09 | $9.82M derived: sum of 2 quarters · filed 2025-10-09 | $13.61M 10-Q · filed 2025-10-09 | $16.99M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $4.08M 10-Q · filed 2025-07-09 | $7.88M 10-Q · filed 2025-07-09 | $11.25M derived: sum of 3 quarters · filed 2026-01-28 | $14.28M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $3.79M 10-Q · filed 2025-04-08 | $7.17M derived: sum of 2 quarters · filed 2026-01-28 | $10.20M derived: sum of 3 quarters · filed 2026-01-28 | $12.69M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $6.41M derived: sum of 2 quarters · filed 2026-01-28 | $8.90M derived: sum of 3 quarters · filed 2026-01-28 | $11.12M 10-K · filed 2026-01-28 |
| 2023-08-31 | $3.03M 10-Q · filed 2024-10-11 | $5.52M derived: sum of 2 quarters · filed 2024-10-11 | $7.74M 10-Q · filed 2024-10-11 | $9.71M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | $2.49M 10-Q · filed 2024-07-11 | $4.71M 10-Q · filed 2024-07-11 | $6.68M derived: sum of 3 quarters · filed 2025-01-28 | $7.69M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | $2.22M 10-Q · filed 2024-04-10 | $4.19M derived: sum of 2 quarters · filed 2025-01-28 | $5.20M derived: sum of 3 quarters · filed 2025-01-28 | $5.51M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | $2.98M derived: sum of 2 quarters · filed 2025-01-28 | $3.30M derived: sum of 3 quarters · filed 2025-01-28 | $3.51M 10-K · filed 2025-01-28 |
| 2022-08-31 | $1.01M 10-Q · filed 2023-10-12 | $1.32M derived: sum of 2 quarters · filed 2023-10-12 | $1.53M 10-Q · filed 2023-10-12 | $1.83M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | $314.00K 10-Q · filed 2023-07-13 | $525.00K 10-Q · filed 2023-07-13 | $820.00K derived: sum of 3 quarters · filed 2023-07-13 | $859.00K derived: sum of 4 quarters · filed 2023-07-13 |
| 2022-02-28 | $211.00K 10-Q · filed 2023-04-13 | $506.00K derived: sum of 2 quarters · filed 2023-04-13 | $545.00K derived: sum of 3 quarters · filed 2023-04-13 | $716.00K derived: sum of 4 quarters · filed 2023-04-13 |
| 2021-11-30 | $295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $334.00K derived: sum of 2 quarters · filed 2023-02-09 | $505.00K derived: sum of 3 quarters · filed 2023-02-09 | $823.00K 10-K · filed 2023-02-09 |
| 2021-08-31 | $39.00K 10-Q · filed 2022-10-06 | $210.00K derived: sum of 2 quarters · filed 2022-10-06 | $528.00K 10-Q · filed 2022-10-06 | $663.00K derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | $171.00K 10-Q · filed 2022-07-07 | $489.00K 10-Q · filed 2022-07-07 | $624.00K derived: sum of 3 quarters · filed 2022-07-07 | $1.30M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $318.00K 10-Q · filed 2022-04-08 | $453.00K derived: sum of 2 quarters · filed 2022-04-08 | $1.13M derived: sum of 3 quarters · filed 2022-04-08 | $1.35M derived: sum of 4 quarters · filed 2022-04-08 |
| 2020-11-30 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $810.00K derived: sum of 2 quarters · filed 2022-01-28 | $1.03M derived: sum of 3 quarters · filed 2022-01-28 | $1.21M 10-K · filed 2022-01-28 |
| 2020-08-31 | $675.00K 10-Q · filed 2021-10-14 | $898.00K derived: sum of 2 quarters · filed 2021-10-14 | $1.07M 10-Q · filed 2021-10-14 | $1.33M derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-05-31 | $223.00K 10-Q · filed 2021-07-13 | $396.00K 10-Q · filed 2021-07-13 | $651.00K derived: sum of 3 quarters · filed 2022-01-28 | $846.00K derived: sum of 4 quarters · filed 2022-01-28 |
| 2020-02-29 | $173.00K 10-Q · filed 2021-04-13 | $428.00K derived: sum of 2 quarters · filed 2022-01-28 | $623.00K derived: sum of 3 quarters · filed 2022-01-28 | |
| 2019-11-30 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | $450.00K derived: sum of 2 quarters · filed 2022-01-28 | $776.00K 10-K · filed 2022-01-28 | |
| 2019-08-31 | $195.00K 10-Q · filed 2020-10-14 | $521.00K 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |